Esperance is developing novel, targeted oncology product candidates that selectively kill cancer cells without harming normal cells. The cationic lytic peptide (CLYPTM) technology platform is delivering multiple membrane disrupting peptides (MDPs) and antibody drug conjugates (ADCs).
EP-302 EP-342 Peptide conjugate Peptide
Product Candidate
Drug Design
Receptor Target
Potential Indications
Development Status
Pending Milestone
EP-100
Peptide conjugate
LHRH
Ovarian, breast, endometrial, prostate, pancreatic, hematologic malignancies
Phase1
Establish maximum tolerated dose
EP-200
Peptide conjugate
LH/hCG
Breast, prostate, endometrial, ovarian
Proof of concept demonstrate in vitro and in vivo
Completion of IND-enabling studies
Nucleolin
AML, Renal, Pancreatic, Prostate
Proof of concept in vitro and in vivo
Select candidate for IND enabling
EP-400 series
Antibody drug conjugates
Multiple
Solid tumors, hematologic malignancies
In vitro studies ongoing
Initiation of in vivo studies